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The  mainstay  of therapy  of large  vessel  vasculitides  (LVV)  remains  glucocorticoids  (GC).  Although  most
patients  initially  achieve  disease  remission,  relapses  and  GC  dependence  are  seen  in  more  than  two-eywords:
arge vessel vasculitis
iant cell arteritis
akayasu arteritis
iological therapies
iotherapies
thirds  of  cases.  Conventional  synthetic  disease-modifying  antirheumatic  drugs  (DMARDs)  showed  little
or  no steroid  sparing  effects,  while  biological  agents  represent  a valid  therapeutic  option  in  patients  with
severe  and/or  relapsing  LVV.
© 2015  Société  nationale  française  de médecine  interne  (SNFMI).  Published  by  Elsevier  Masson  SAS.
All rights  reserved.. Introduction
Glucocorticoids (GC) are the mainstay of treatment in large
essel vasculitides (LVV), but in patients with relapsing-remitting
isease, biological agents may  represent a valid therapeutic option.
nterleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are
ighly expressed in the inﬂamed arteries tissues; their serum
oncentration is higher in the subgroup of patients with strong
cute-phase response and higher corticosteroids requirements.
ecent data showed that disturbances of B cell homeostasis are
lso critical in LVV patients. All these data support the rationale of
he use of anti-TNF, anti-IL-6 and anti-CD20 biological agents in
VV. Herein, we summarized the main evidence regarding the use
f biological agents in large vessel vasculitis.
. Anti-TNF
.1. Giant cell arteritis
The mainstay of therapy of newly diagnosed giant cell arteritis
GCA) remains glucocorticoids (GC). Only three randomized clinical
rials (RCT) investigated the efﬁcacy of anti-TNF agents in GCA,
wo enrolling patients with newly diagnosed GCA [1,2], the third
ne enrolling patients with longstanding GCA [3].
The ﬁrst RCT [1] was conducted in 44 patients newly diagnosed
CA after GC-induced remission. Sixteen of these patients were
∗ Corresponding author.
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248-8663/© 2015 Société nationale française de médecine interne (SNFMI). Published brandomly assigned to receive GC plus placebo and 28 patients to
GC plus intravenous inﬂiximab (IFX) at a dose of 5 mg/kg of body
weight at weeks 0, 2, and 6 and every 8 weeks thereafter. At week
22, IFX therapy did not increase the proportion of patients without
relapse compared with placebo, nor did it increase the proportion
of patients whose GC was tapered to 10 mg/day without relapse [1].
The second study [2] investigated the effect of adding to stan-
dard treatment with GC a 10-week treatment of adalimumab (ADA)
(40 mg every other week) in 70 patients with newly diagnosed GCA.
The primary endpoint (the percentage of patients in remission on
less than 0.1 mg/kg of prednisone at week 26) was  not achieved [2].
The third study [3] evaluated the role of TNF blockade
in longstanding GCA: the study was conducted in a popula-
tion of 17 patients requiring a prednisone dose > 10 mg/day and
with a least one GC-related adverse event, randomized to group
A, etanercept (ETA) plus GC or group B, placebo plus GC. At
12 months, 50% of patients in ETA group and 22% of those in the
placebo group were able to adequately control disease activity
without GC therapy, but the between-group difference was not
signiﬁcant [3]. However, patients in the ETA group had a signif-
icant lower cumulative prednisone dose during the ﬁrst year of
treatment.
Taken together, these results suggest that TNF blockers are
ineffective or can have only a marginal beneﬁcial effect in newly
diagnosed GCA, although the limited number of patients included
does not allow to draw deﬁnitive conclusions. In contrast, in addi-
tion the RCT mentioned above, one open pilot study and case
reports have shown efﬁcacy of anti-TNF drugs in reducing GC
requirements in GCA patients with longstanding, relapsing dis-
ease [4–6]. This suggests that TNF inhibitors may have a role in
relapsing and/or refractory GCA.
y Elsevier Masson SAS. All rights reserved.
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Table 1
Summary of case series using biological agents in GCAc.
Study Biological agent Number of
patients
Median age
(range [y])
Female
proportion
Median disease
duration
(mo, [range])
Remission
rate
Median CRP Median prednisone
(mg/d)
Pts w/o
prednisone
in remission
Relapse
rate
Median
follow-up
period
Before After Before After
Beyer et al., 2011 [23]a,b TCZ 3 72
(71–79)
2/3 NR 3/3 34.9 < 4 30 < 7.5 0/3 0/3 6
Sciascia  et al., 2011 [20] TCZ 2 76.5
(76–77)
2/2 NR 2/2 NR NR 25 5 0/2 0/2 7
Seitz  et al., 2011 [21]a TCZ (2 monoRx) 5 71
(63–79)
3/5 6
(3–56)
5/5 14 < 3 20 5 3/5 0/5 8.3
Salvarani et al., 2012 [22]a,b TCZ (1 monoRx) 2 59
(54–64)
0/2 19
(2, 36)
2/2 51 0.4 12.5 1.25 1/2 1/2 9.5
Unizony  et al., 2012 [25]b TCZ 7 69
(60–83)
NR NR
(10–24)
7/7 34 0.7 15 0.5 4/7 2/7 7
Cantini  et al., 2001 [4]b IFX 4 74
(72–75)
3/4 47.5
(42–54)
3/4 46 3 12.5 0 3/4 0/3 5
Andonopoulos et al., 2003 [5] IFX 2 82.5
(80–85)
0/2 NR 2/2 51 0.4 0 0 1/2 2/2 4.5
Three studies (Seitz et al., 2011 [21], Salvarani et al., 2012 [22] and Unizony et al., 2012 [25]) also appear in Table 2 with TAK patients.
GCA:  giant cell arteritis; TCZ: tocilizumab; monoRx: monotherapy; IFX: inﬂiximab; CRP: C-reactive protein; NR: not reported; TAK: Takayasu arteritis; F/U: follow-up; mo: month; y: year.
a In these studies, remission was deﬁned using clinical, biochemical and the absence of new radiographic ﬁndings.
b In these studies, F/U was  6 mo  while patients were in remission.
c Reproduced from Osman et al. [43].
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Table 2
Summary of case series using biological agents in TAKd.
Study Biological agent Number of
patients
Median age
(range [y])
Female
proportion
Median disease
duration
(mo, [range])
Remission
rate
Median CRP Median prednisone
(mg/d)
Pts w/o
prednisone
in remission
Relapse
rate
Median
follow-up
period
Before After Before After
Seitz et al., 2011 [21]a TCZ 2 33.5
(27–40)
2/2 57
(42–72)
1/2 45.5 3 35 2.5 0/2 1/1 6
Salvarani  et al., 2012 [22]a,b TCZ (1 monoRx) 2 30.5
(21–40)
2/2 7.5
(3, 12)
2/2 40.2 8.5 12.5 0 2/2 0/2 8.5
Unizony  et al., 2012 [25] TCZ 2 41.5 2/2 NR 2/2 12.3 2.95 5 0 2/2 0/2 9.5
Canas  et al., 2012 [47]b TCZ 5 30
(12–32)
3/3 48
(3–96)
3/3 26.1 1 NR (< 10) NR(< 10) 0/2 0/5 6
Galarza  et al., 2008 [48] RXB 2 27
(27–29)
2/2 NR 2/2 NR NR NR NR NR NR NR
Hoyer  et al., 2012 [42]a RXB 3 18
(12–31)
3/3 48
(48-120)
3/3 90 5 7.5 7.5 0/3 NR NR
Della  Rossa et al., 2005 [49]b IFX 2 19.5
(16–23)
2/2 35
(35–40)
2/2 68.5 NR 8 2 1/2 0/2 8.5
Hoffman  et al., 2004 [10]a,b,c IFX 8/15 28.5
(17–48)
14/15 60
(15–110)
7/8 NR NR 20 2.5 3/8 5/8 11
(3–40)
ETN  to IFX 2/15 23.5
(19–28)
15
(12–18)
2/2 NR NR 22.5 0 2/2 2/2 32.5
(17–48)
ETN  5/15 25
(19–42)
30
(2–160)
5/5 NR NR 20 0 5/5 5/5 28
(11–35)
Molloy  et al., 2008 [11]a,b,c IFX 21/25 35
(15–64)
22/25 116
(39–344)
23/21 NR NR 19 (5–50) 0 (0–30) 12/21 2/12 28
(4–82)
ETN  4/25 3/4 NR NR 2/3 2/4
Karageorgaki et al., 2007 [50]a,b IFX 4 25
(17–32)
4/4 57
(24–86)
2/4 54 16 5.63 8.75 0/4 1/2 14
Filocamo  et al., 2008 [51]b IFX 4 11.5
(7–12)
4/4 10.5
(1–30)
2/4 NR NR NA 5 0/2 2/4 6
Nunes  et al., 2010 [52]a,b IFX 3/15 Rx IFX 21
(17–21)
3/3 48
(24–180)
3/3 NR NR 20 10 1/3 NR 6–10
Kaneko  et al., 2010 [44]b IFX 3 17
(16–17)
3/3 6
(3–11)
2/3 NR NR 20 0 2/3 1/2 6
Buonuomo et al., 2011 [45]b IFX 2 15
(14–16)
3/3 6
(3–11)
2/3 NR NR 0.5 mg/kg NR 0/2 0/2 NR
Osman  et al., 2014 [43] IFX then ADA 2 28
(17–39)
2/2 28 0/2 NR NR 40 25 NA NA NR
Comarmond et al., 2012 [14]b IFX 2 26
(24–28)
0/2 21
(6–36)
2/2 59 < 4 22.5 5 0/2 0/2 101.5
Mekinian  et al., 2012 [46]b IFX 15 41
(17–61)
13/15 36
(6–365)
11/15 30 9 20 6 1/15 4/11 43
Schmidt  et al., 2012 [12]a,b IFX 17/20 29.8
(30–44)
19/20 15.9
(2–32.7)
18/20 10 NR 12.2(3–25) NR 7/12 6/18 54
(34–82)
ADA  2/20
ETN 1/20
TCZ: tocilizumab; monoRx: monotherapy; IFX: inﬂiximab; CRP: C-reactive protein; NR: not reported; NA: not applicable; F/U: follow-up; RXB: rituximab; ETN: etanercept; ADA: adalimumab; mo:  month; y: year.
a In these studies, remission was deﬁned using clinical, biochemical and the absence of new radiographic ﬁndings.
b In these studies, F/U was  6 mo  while patients were in remission.
c These two studies were from the same cohort and the latter was a follow-up of the initial one.
d Reproduced from Osman et al. [43].
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.2. Takayasu arteritis
As in GCA, GC are still the mainstay of treatment for Takayasu
rteritis (TAK) [7]. However, although most patients initially
chieve disease remission, relapses and GC dependence are seen
n more than two-thirds of patients [8]: between 46 and 84% of
atients will need a second agent to achieve sustained remission
ith acceptable GC dosages [9].
In TAK, anti-TNF agents have not been formally tested in RCT.
n an open label trial of 15 patients with TAK, the addition of anti-
NF therapy (IFX or ETA) to GC resulted in improvement in 14 of
5 patients and in a sustained remission in 10 of 15 patients that
ecame able to discontinue GC therapy [10].
A retrospective study of 25 patients with refractory TAK showed
hat anti-TNF therapy led to sustained remission in the majority
f patients (88%) [11].
Other retrospective [12] and uncontrolled studies suggest that
nti-TNF blockade may  have a role in the treatment of refractory
AK. Noteworthy, two case series and a literature review reported,
espectively, 120 and 163 TAK patients treated with anti-TNF
gents [13,14]. These reports provide observational evidence that
nti-TNF blockers are able to induce remission in the majority
70–90%) of TAK patients unable to achieve or maintain remis-
ion with GC and synthetic immunosuppressors alone. The most
ommonly used anti-TNF agent is IFX (5 mg/kg of body weight at
eeks 0, 2, and 6 and every 8 weeks thereafter), often associated
ith MTX, followed by ETA and ADA [13,14]. These data encour-
ge the use of anti-TNF agents in remitting-relapsing disease,
lthough RCT to properly evaluate the efﬁcacy of anti-TNF therapy
n TAK are needed.
. Interleukin-6 antibody
.1. Giant cell arteritis
In GCA patients, IL-6 is upregulated within the inﬂamed arter-
es and in the peripheral circulation [15–17]. Furthermore, IL-6
nduces the production of acute-phase reactants, causes consti-
utional manifestations, which are typical features of large vessel
asculitis; conversely, IL-6 levels decline with effective GC therapy.
his data suggests a potential therapeutic role for the IL-6 recep-
or inhibitor monoclonal antibody tocilizumab (TCZ) [18,19]. Case
eports and small case series have shown the efﬁcacy of TCZ in
he treatment of patients with relapsing/refractory GCA [20–33].
n the majority of reports, TCZ (at the dose of 4 mg/kg/monthly
r more often 8 mg/kg/monthly) rapidly improved clinical man-
festations and laboratory parameters and was  generally well
olerated. Altogether, TCZ has been used so far in over 30 patients
ith GCA, half of whom had cranial and half systemic manifes-
ations. Nearly all patients were receiving GC, while six were
C-naive. A partial or complete clinical response was observed
n over 90% of patients, while imaging ﬁndings improved or
esolved in the 7 patients for whom data were made available.
owever, the number of patients with ischemic manifestations
as too limited to establish whether TCZ is also effective in this
egard.
The GiACTA trial (a phase III, multicentre, randomized, double-
lind placebo-controlled study to assess the efﬁcacy and safety
f tocilizumab in subjects with giant cell arteritis, ClinicalTri-
ls.gov Identiﬁer NCT01791153), aimed at assessing the efﬁcacy
nd safety of TCZ in GCA is currently ongoing [34]. It is the
argest RCT in GCA, aiming to recruit 250 patients worldwide.
t is expected that the results will be available in a few years.
thers RCT are required to deﬁne the precise role of TCZ in
CA.ne interne 37 (2016) 274–278 277
3.2. Takayasu arteritis
As in GCA, IL-6 is thought to play a key role in the pathogenesis
of TAK. Case reports and small case series have shown efﬁcacy and
safety of TCZ in the treatment of patients with relapsing/refractory
TAK (approximately 20 cases) [21,22,25,35–40]. Similarly to GCA,
TCZ at a dose of 8 mg/kg every 4 weeks appears to be effective for
treating relapsing/refractory TAK patients. In most patients, TCZ
was able to consistently suppress disease activity and allow taper
of GC [13]. TAK patients naive to GC and immunosuppressive agents
have also been demonstrated to respond well to TCZ monotherapy
[25,27]. However, worsening of vascular lesions on imaging despite
a favorable clinical and laboratory response has been reported,
albeit infrequently [37].
Proper RCT are required to assess the efﬁcacy of anti-IL-6 (-
receptor) therapies.
4. Anti-B cell therapy
4.1. Takayasu arteritis
There is increasing evidence about the role of B cells in the
pathogenesis of TAK. Data from immune-histochemical analyses
of aortic wall samples in patients with TA have shown that B cells
are found in the inﬂamed arterial adventitia [36]. Furthermore, B
cell subsets in the peripheral blood of patients with TA were sig-
niﬁcantly higher than in matched healthy donors and similar to
those found in SLE controls. In particular, a high number of newly
generated plasmablasts was observed [37]. These ﬁndings sug-
gest a potential role for B cell depleting therapy in TAK. There are
few reports of patients with active relapsing/remitting TAK despite
multiple immunosuppressive agents, including anti-TNF agents,
that have successfully been treated with rituximab (RTX) (1 g at
day 0 and 15) [41,42]. However, although RTX may  be a possible
treatment in refractory TAK, the number of studies and patients is
limited, thus RCT and prospective studies are needed.
Tables 1 and 2 summarize case series using biological agents in
GCA and TAK respectively [43].
5. Other biotherapies
A trial (Abatacept for Treating Adults With Giant Cell
Arteritis and Takayasu’s Arteritis, ClinicalTrials.gov Identiﬁer
NCT00556439) evaluating the efﬁcacy of abatacept in LVV recently
closed the enrolment. In this study, all participants receive abata-
cept and prednisone with a tapering scheme for the ﬁrst 3 months.
At month 3, the patients that will achieve remission will be ran-
domly assigned to receive monthly infusions of either abatacept or
placebo. The primary outcome of the study is the duration of the
remission; the secondary main outcome is the safety. The results
of this study will be available in a few years.
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